4 suspended. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Suspended 4 |
| Phase 2 | 1 | Suspended 1 |
Follow Immunoblastic Lymphadenopathy: new trials by email Literature Review of Immunoblastic Lymphadenopathy trials Research Report on Immunoblastic Lymphadenopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells - Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 60 | 2025-09-29 | 2026-10-16 |
| A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Brincidofovir - Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | Suspended | SymBio Pharmaceuticals | 43 | 2025-06-09 | 2026-02-05 |
| Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies WU-CART-007 - T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia | Phase 1 | Suspended | Washington University School of Medicine | 6 | 2023-10-10 | 2026-07-21 |
| Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies anti-TRBC1 CAR-T cell therapy - Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | Suspended | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 9 | 2021-03-31 | 2023-11-29 |
Lymphoma, Large-Cell, Anaplastic (3) · Lymphoma, T-Cell, Peripheral (3) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (3) · Enteropathy-Associated T-Cell Lymphoma (2) · Lymphoma, T-Cell (2) · Epstein-Barr Virus Infections (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Prolymphocytic, T-Cell (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Lymphoma (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphadenopathy (4) · Lymphatic Diseases (4) · Lymphoma, Non-Hodgkin (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Hematologic Diseases (3) · Leukemia (3) · Leukemia, Lymphoid (3) · Lymphoma (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, T-Cell (2)
Cyclophosphamide (1) · brincidofovir (1) · fludarabine (1)
National Cancer Institute (NCI) (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · SymBio Pharmaceuticals (1) · Washington University School of Medicine (1)
China (2) · United States (2) · Japan (1) · Singapore (1)
Geoffrey Uy, M.D. (1) · Samuel Y Ng, M.D. (1)